{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,8]],"date-time":"2026-10-08T18:21:56Z","timestamp":1791483716350,"version":"4.3.4"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8","license":[{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T00:00:00Z","timestamp":1661731200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/100000053","name":"U.S. Department of Health & Human Services | NIH | National Eye Institute","doi-asserted-by":"publisher","award":["4 R00 EY029373-03"],"award-info":[{"award-number":["4 R00 EY029373-03"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000053","name":"U.S. Department of Health & Human Services | NIH | National Eye Institute","doi-asserted-by":"publisher","award":["EY11766"],"award-info":[{"award-number":["EY11766"]}],"id":[{"id":"10.13039\/100000053","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100006812","name":"Center for Integrated Healthcare, U.S. Department of Veterans Affairs","doi-asserted-by":"publisher","award":["BX001233"],"award-info":[{"award-number":["BX001233"]}],"id":[{"id":"10.13039\/100006812","id-type":"DOI","asserted-by":"publisher"}]},{"name":"U.S. Department of Health & Human Services | NIH | National Eye Institute"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Cell Death Dis"],"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Current therapies for treatment of proliferative retinopathy focus on retinal neovascularization (RNV) during advanced disease and can trigger adverse side-effects. Here, we have tested a new strategy for limiting neurovascular injury and promoting repair during early-stage disease. We have recently shown that treatment with a stable, pegylated drug form of the ureohydrolase enzyme arginase 1 (A1) provides neuroprotection in acute models of ischemia\/reperfusion injury, optic nerve crush, and ischemic stroke. Now, we have determined the effects of this treatment on RNV, vascular repair, and retinal function in the mouse oxygen-induced retinopathy (OIR) model of retinopathy of prematurity (ROP). Our studies in the OIR model show that treatment with pegylated A1 (PEG-A1), inhibits pathological RNV, promotes angiogenic repair, and improves retinal function by a mechanism involving decreased expression of TNF, iNOS, and VEGF and increased expression of FGF2 and A1. We further show that A1 is expressed in myeloid cells and areas of RNV in retinal sections from mice with OIR and human diabetic retinopathy (DR) patients and in blood samples from ROP patients. Moreover, studies using knockout mice with hemizygous deletion of A1 show worsened RNV and retinal injury, supporting the protective role of A1 in limiting the OIR-induced pathology. Collectively, A1 is critically involved in reparative angiogenesis and neuroprotection in OIR. Pegylated A1 may offer a novel therapy for limiting retinal injury and promoting repair during proliferative retinopathy.<\/jats:p>","DOI":"10.1038\/s41419-022-05196-8","type":"journal-article","created":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T10:03:45Z","timestamp":1661767425000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":31,"title":["Targeting proliferative retinopathy: Arginase 1 limits vitreoretinal neovascularization and promotes angiogenic repair"],"prefix":"10.1038","volume":"13","author":[{"ORCID":"https:\/\/orcid.org\/0000-0003-3042-9425","authenticated-orcid":false,"given":"Abdelrahman Y.","family":"Fouda","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zhimin","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jutamas","family":"Suwanpradid","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Modesto","family":"Rojas","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Esraa","family":"Shosha","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tahira","family":"Lemtalsi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chintan","family":"Patel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ji","family":"Xing","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Syed A.","family":"Zaidi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wenbo","family":"Zhi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Brain K.","family":"Stansfield","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul Ning-Man","family":"Cheng","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S. Priya","family":"Narayanan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R. William","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0168-0354","authenticated-orcid":false,"given":"Ruth B.","family":"Caldwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2022,8,29]]},"reference":[{"key":"5196_CR1","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1007\/s00417-010-1315-z","volume":"248","author":"BP Nicholson","year":"2010","unstructured":"Nicholson BP, Schachat AP. A review of clinical trials of anti-VEGF agents for diabetic retinopathy. Graefe\u2019s Arch Clin Exp Ophthalmol. 2010;248:915\u201330.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"5196_CR2","first-page":"91","volume":"8","author":"R Liegl","year":"2016","unstructured":"Liegl R, Hellstrom A, Smith LE. Retinopathy of prematurity: the need for prevention. Eye Brain. 2016;8:91\u2013102.","journal-title":"Eye Brain"},{"key":"5196_CR3","doi-asserted-by":"publisher","first-page":"257","DOI":"10.1016\/j.survophthal.2016.12.004","volume":"62","author":"ME Hartnett","year":"2017","unstructured":"Hartnett ME. Advances in understanding and management of retinopathy of prematurity. Surv Ophthalmol. 2017;62:257\u201376.","journal-title":"Surv Ophthalmol"},{"key":"5196_CR4","doi-asserted-by":"publisher","first-page":"129","DOI":"10.3109\/08820538.2013.835833","volume":"30","author":"R Nuzzi","year":"2015","unstructured":"Nuzzi R, Tridico F. Local and systemic complications after intravitreal administration of anti-vascular endothelial growth factor agents in the treatment of different ocular diseases: a five-year retrospective study. Semin Ophthalmol. 2015;30:129\u201335.","journal-title":"Semin Ophthalmol"},{"key":"5196_CR5","doi-asserted-by":"publisher","first-page":"787","DOI":"10.1038\/eye.2013.107","volume":"27","author":"KG Falavarjani","year":"2013","unstructured":"Falavarjani KG, Nguyen QD. Adverse events and complications associated with intravitreal injection of anti-VEGF agents: a review of literature. Eye (Lond, Engl). 2013;27:787\u201394.","journal-title":"Eye (Lond, Engl)"},{"key":"5196_CR6","doi-asserted-by":"publisher","first-page":"e22460","DOI":"10.1371\/journal.pone.0022460","volume":"6","author":"SP Narayanan","year":"2011","unstructured":"Narayanan SP, Suwanpradid J, Saul A, Xu Z, Still A, Caldwell RW, et al. Arginase 2 deletion reduces neuro-glial injury and improves retinal function in a model of retinopathy of prematurity. PLoS ONE. 2011;6:e22460.","journal-title":"PLoS ONE"},{"key":"5196_CR7","doi-asserted-by":"publisher","first-page":"e1075","DOI":"10.1038\/cddis.2014.23","volume":"5","author":"SP Narayanan","year":"2014","unstructured":"Narayanan SP, Xu Z, Putluri N, Sreekumar A, Lemtalsi T, Caldwell RW, et al. Arginase 2 deficiency reduces hyperoxia-mediated retinal neurodegeneration through the regulation of polyamine metabolism. Cell Death Dis. 2014;5:e1075.","journal-title":"Cell Death Dis"},{"key":"5196_CR8","doi-asserted-by":"publisher","first-page":"e110604","DOI":"10.1371\/journal.pone.0110604","volume":"9","author":"J Suwanpradid","year":"2014","unstructured":"Suwanpradid J, Rojas M, Behzadian MA, Caldwell RW, Caldwell RB. Arginase 2 deficiency prevents oxidative stress and limits hyperoxia-induced retinal vascular degeneration. PLoS ONE. 2014;9:e110604.","journal-title":"PLoS ONE"},{"key":"5196_CR9","doi-asserted-by":"publisher","first-page":"e2483","DOI":"10.1038\/cddis.2016.295","volume":"7","author":"E Shosha","year":"2016","unstructured":"Shosha E, Xu Z, Yokota H, Saul A, Rojas M, Caldwell RW, et al. Arginase 2 promotes neurovascular degeneration during ischemia\/reperfusion injury. Cell Death Dis. 2016;7:e2483.","journal-title":"Cell Death Dis"},{"key":"5196_CR10","doi-asserted-by":"publisher","first-page":"970","DOI":"10.3389\/fnins.2018.00970","volume":"12","author":"Z Xu","year":"2018","unstructured":"Xu Z, Fouda AY, Lemtalsi T, Shosha E, Rojas M, Liu F, et al. Retinal neuroprotection from optic nerve trauma by deletion of arginase 2. Front Neurosci. 2018;12:970.","journal-title":"Front Neurosci"},{"key":"5196_CR11","doi-asserted-by":"publisher","first-page":"1001","DOI":"10.1038\/s41419-018-1051-6","volume":"9","author":"AY Fouda","year":"2018","unstructured":"Fouda AY, Xu Z, Shosha E, Lemtalsi T, Chen J, Toque HA, et al. Arginase 1 promotes retinal neurovascular protection from ischemia through suppression of macrophage inflammatory responses. Cell Death Dis. 2018;9:1001.","journal-title":"Cell Death Dis"},{"key":"5196_CR12","doi-asserted-by":"publisher","first-page":"641","DOI":"10.1152\/physrev.00037.2016","volume":"98","author":"RW Caldwell","year":"2018","unstructured":"Caldwell RW, Rodriguez PC, Toque HA, Narayanan SP, Caldwell RB. Arginase: a multifaceted enzyme important in health and disease. Physiol Rev. 2018;98:641\u201365.","journal-title":"Physiol Rev"},{"key":"5196_CR13","doi-asserted-by":"publisher","first-page":"113923","DOI":"10.1016\/j.expneurol.2021.113923","volume":"348","author":"AY Fouda","year":"2021","unstructured":"Fouda AY, Eldahshan W, Xu Z, Lemtalsi T, Shosha E, Zaidi SA, et al. Preclinical investigation of Pegylated arginase 1 as a treatment for retina and brain injury. Exp Neurol. 2021;348:113923.","journal-title":"Exp Neurol"},{"key":"5196_CR14","first-page":"101","volume":"35","author":"LE Smith","year":"1994","unstructured":"Smith LE, Wesolowski E, McLellan A, Kostyk SK, D\u2019Amato R, Sullivan R, et al. Oxygen-induced retinopathy in the mouse. Investigative Ophthalmol Vis Sci. 1994;35:101\u201311.","journal-title":"Investigative Ophthalmol Vis Sci"},{"key":"5196_CR15","doi-asserted-by":"publisher","first-page":"1565","DOI":"10.1038\/nprot.2009.187","volume":"4","author":"KM Connor","year":"2009","unstructured":"Connor KM, Krah NM, Dennison RJ, Aderman CM, Chen J, Guerin KI, et al. Quantification of oxygen-induced retinopathy in the mouse: a model of vessel loss, vessel regrowth and pathological angiogenesis. Nat Protoc. 2009;4:1565\u201373.","journal-title":"Nat Protoc"},{"key":"5196_CR16","doi-asserted-by":"publisher","first-page":"67","DOI":"10.2147\/EB.S94447","volume":"8","author":"CB Kim","year":"2016","unstructured":"Kim CB, D\u2019Amore PA, Connor KM. Revisiting the mouse model of oxygen-induced retinopathy. Eye Brain. 2016;8:67\u201379.","journal-title":"Eye Brain"},{"key":"5196_CR17","doi-asserted-by":"publisher","first-page":"309","DOI":"10.1158\/0008-5472.CAN-06-1945","volume":"67","author":"PN Cheng","year":"2007","unstructured":"Cheng PN, Lam TL, Lam WM, Tsui SM, Cheng AW, Lo WH, et al. Pegylated recombinant human arginase (rhArg-peg5,000mw) inhibits the in vitro and in vivo proliferation of human hepatocellular carcinoma through arginine depletion. Cancer Res. 2007;67:309\u201317.","journal-title":"Cancer Res"},{"key":"5196_CR18","doi-asserted-by":"publisher","first-page":"1205","DOI":"10.1007\/s00417-009-1116-4","volume":"247","author":"C Lange","year":"2009","unstructured":"Lange C, Ehlken C, Stahl A, Martin G, Hansen L, Agostini HT. Kinetics of retinal vaso-obliteration and neovascularisation in the oxygen-induced retinopathy (OIR) mouse model. Graefe\u2019s Arch Clin Exp Ophthalmol. 2009;247:1205\u201311.","journal-title":"Graefe\u2019s Arch Clin Exp Ophthalmol"},{"key":"5196_CR19","first-page":"496","volume":"43","author":"X Gu","year":"2002","unstructured":"Gu X, Samuel S, El-Shabrawey M, Caldwell RB, Bartoli M, Marcus DM, et al. Effects of sustained hyperoxia on revascularization in experimental retinopathy of prematurity. Investigative Ophthalmol Vis Sci. 2002;43:496\u2013502.","journal-title":"Investigative Ophthalmol Vis Sci"},{"key":"5196_CR20","doi-asserted-by":"publisher","first-page":"891","DOI":"10.2353\/ajpath.2009.081115","volume":"175","author":"W Zhang","year":"2009","unstructured":"Zhang W, Baban B, Rojas M, Tofigh S, Virmani SK, Patel C, et al. Arginase activity mediates retinal inflammation in endotoxin-induced uveitis. Am J Pathol. 2009;175:891\u2013902.","journal-title":"Am J Pathol"},{"key":"5196_CR21","doi-asserted-by":"publisher","first-page":"654","DOI":"10.1007\/s00125-012-2789-5","volume":"56","author":"SC Elms","year":"2013","unstructured":"Elms SC, Toque HA, Rojas M, Xu Z, Caldwell RW, Caldwell RB. The role of arginase I in diabetes-induced retinal vascular dysfunction in mouse and rat models of diabetes. Diabetologia 2013;56:654\u201362.","journal-title":"Diabetologia"},{"key":"5196_CR22","doi-asserted-by":"publisher","first-page":"173","DOI":"10.3389\/fimmu.2013.00173","volume":"4","author":"C Patel","year":"2013","unstructured":"Patel C, Rojas M, Narayanan SP, Zhang W, Xu Z, Lemtalsi T, et al. Arginase as a mediator of diabetic retinopathy. Front Immunol. 2013;4:173.","journal-title":"Front Immunol"},{"key":"5196_CR23","doi-asserted-by":"publisher","first-page":"663","DOI":"10.1016\/j.survophthal.2009.02.021","volume":"54","author":"BV Davitt","year":"2009","unstructured":"Davitt BV, Wallace DK. Plus disease. Surv Ophthalmol. 2009;54:663\u201370.","journal-title":"Surv Ophthalmol"},{"key":"5196_CR24","doi-asserted-by":"publisher","first-page":"4017","DOI":"10.1167\/iovs.15-18508","volume":"57","author":"F Bucher","year":"2016","unstructured":"Bucher F, Walz JM, Buhler A, Aguilar E, Lange C, Diaz-Aguilar S, et al. CNTF attenuates vasoproliferative changes through upregulation of SOCS3 in a mouse-model of oxygen-induced retinopathy. Investigative Ophthalmol Vis Sci. 2016;57:4017\u201326.","journal-title":"Investigative Ophthalmol Vis Sci"},{"key":"5196_CR25","doi-asserted-by":"publisher","first-page":"43","DOI":"10.1002\/glia.20900","volume":"58","author":"MI Dorrell","year":"2010","unstructured":"Dorrell MI, Aguilar E, Jacobson R, Trauger SA, Friedlander J, Siuzdak G, et al. Maintaining retinal astrocytes normalizes revascularization and prevents vascular pathology associated with oxygen-induced retinopathy. Glia 2010;58:43\u201354.","journal-title":"Glia"},{"key":"5196_CR26","doi-asserted-by":"publisher","first-page":"e32167","DOI":"10.1371\/journal.pone.0032167","volume":"7","author":"S Nakamura","year":"2012","unstructured":"Nakamura S, Imai S, Ogishima H, Tsuruma K, Shimazawa M, Hara H. Morphological and functional changes in the retina after chronic oxygen-induced retinopathy. PLoS ONE. 2012;7:e32167.","journal-title":"PLoS ONE"},{"key":"5196_CR27","doi-asserted-by":"publisher","first-page":"1268","DOI":"10.1097\/OPX.0000000000000941","volume":"93","author":"OJ Mezu-Ndubuisi","year":"2016","unstructured":"Mezu-Ndubuisi OJ. In vivo angiography quantifies oxygen-induced retinopathy vascular recovery. Optom Vis Sci. 2016;93:1268\u201379.","journal-title":"Optom Vis Sci"},{"key":"5196_CR28","first-page":"257","volume":"26","author":"OJ Mezu-Ndubuisi","year":"2020","unstructured":"Mezu-Ndubuisi OJ, Macke EL, Kalavacherla R, Nwaba AA, Suscha A, Zaitoun IS, et al. Long-term evaluation of retinal morphology and function in a mouse model of oxygen-induced retinopathy. Mol Vis. 2020;26:257\u201376.","journal-title":"Mol Vis"},{"key":"5196_CR29","doi-asserted-by":"publisher","first-page":"1366","DOI":"10.1038\/sj.eye.6702138","volume":"20","author":"N Demircan","year":"2006","unstructured":"Demircan N, Safran BG, Soylu M, Ozcan AA, Sizmaz S. Determination of vitreous interleukin-1 (IL-1) and tumour necrosis factor (TNF) levels in proliferative diabetic retinopathy. Eye (Lond, Engl). 2006;20:1366\u20139.","journal-title":"Eye (Lond, Engl)"},{"key":"5196_CR30","doi-asserted-by":"publisher","first-page":"747","DOI":"10.3129\/i06-070","volume":"41","author":"MC Mocan","year":"2006","unstructured":"Mocan MC, Kadayifcilar S, Eldem B. Elevated intravitreal interleukin-6 levels in patients with proliferative diabetic retinopathy. Can J Ophthalmol. 2006;41:747\u201352.","journal-title":"Can J Ophthalmol"},{"key":"5196_CR31","doi-asserted-by":"publisher","first-page":"218","DOI":"10.1016\/S0021-5155(01)00497-X","volume":"46","author":"Y Mitamura","year":"2002","unstructured":"Mitamura Y, Takeuchi S, Yamamoto S, Yamamoto T, Tsukahara I, Matsuda A, et al. Monocyte chemotactic protein-1 levels in the vitreous of patients with proliferative vitreoretinopathy. Jpn J Ophthalmol. 2002;46:218\u201321.","journal-title":"Jpn J Ophthalmol"},{"key":"5196_CR32","doi-asserted-by":"crossref","unstructured":"Nawaz IM, Rezzola S, Cancarini A, Russo A, Costagliola C, Semeraro F, et al. Human vitreous in proliferative diabetic retinopathy: Characterization and translational implications. Prog Retinal Eye Res. 2019;72:100756.","DOI":"10.1016\/j.preteyeres.2019.03.002"},{"key":"5196_CR33","doi-asserted-by":"publisher","first-page":"637","DOI":"10.1016\/S0002-9440(10)62284-5","volume":"166","author":"TA Gardiner","year":"2005","unstructured":"Gardiner TA, Gibson DS, de Gooyer TE, de la Cruz VF, McDonald DM, Stitt AW. Inhibition of tumor necrosis factor-alpha improves physiological angiogenesis and reduces pathological neovascularization in ischemic retinopathy. Am J Pathol. 2005;166:637\u201344.","journal-title":"Am J Pathol"},{"key":"5196_CR34","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1189\/jlb.0302117","volume":"73","author":"S Yoshida","year":"2003","unstructured":"Yoshida S, Yoshida A, Ishibashi T, Elner SG, Elner VM. Role of MCP-1 and MIP-1alpha in retinal neovascularization during postischemic inflammation in a mouse model of retinal neovascularization. J Leukoc Biol. 2003;73:137\u201344.","journal-title":"J Leukoc Biol"},{"key":"5196_CR35","doi-asserted-by":"crossref","unstructured":"Arima M, Fujii Y, Sonoda KH. Translational research in retinopathy of prematurity: from bedside to bench and back again. J Clin Med. 2021;10:331.","DOI":"10.3390\/jcm10020331"},{"key":"5196_CR36","doi-asserted-by":"publisher","first-page":"eaay1371","DOI":"10.1126\/scitranslmed.aay1371","volume":"12","author":"Z Liu","year":"2020","unstructured":"Liu Z, Xu J, Ma Q, Zhang X, Yang Q, Wang L, et al. Glycolysis links reciprocal activation of myeloid cells and endothelial cells in the retinal angiogenic niche. Sci Transl Med. 2020;12:eaay1371.","journal-title":"Sci Transl Med"},{"key":"5196_CR37","doi-asserted-by":"publisher","first-page":"717","DOI":"10.1172\/JCI10874","volume":"107","author":"F Sennlaub","year":"2001","unstructured":"Sennlaub F, Courtois Y, Goureau O. Inducible nitric oxide synthase mediates the change from retinal to vitreal neovascularization in ischemic retinopathy. J Clin Investig. 2001;107:717\u201325.","journal-title":"J Clin Investig"},{"key":"5196_CR38","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1523\/JNEUROSCI.22-10-03987.2002","volume":"22","author":"F Sennlaub","year":"2002","unstructured":"Sennlaub F, Courtois Y, Goureau O. Inducible nitric oxide synthase mediates retinal apoptosis in ischemic proliferative retinopathy. J Neurosci: Off J Soc Neurosci. 2002;22:3987\u201393.","journal-title":"J Neurosci: Off J Soc Neurosci"},{"key":"5196_CR39","doi-asserted-by":"publisher","first-page":"4843","DOI":"10.1073\/pnas.0735876100","volume":"100","author":"J Lee","year":"2003","unstructured":"Lee J, Ryu H, Ferrante RJ, Morris SM Jr., Ratan RR. Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proc Natl Acad Sci USA. 2003;100:4843\u20138.","journal-title":"Proc Natl Acad Sci USA"},{"key":"5196_CR40","doi-asserted-by":"publisher","first-page":"189","DOI":"10.1182\/blood.V95.1.189","volume":"95","author":"H Kimura","year":"2000","unstructured":"Kimura H, Weisz A, Kurashima Y, Hashimoto K, Ogura T, D\u2019Acquisto F, et al. Hypoxia response element of the human vascular endothelial growth factor gene mediates transcriptional regulation by nitric oxide: control of hypoxia-inducible factor-1 activity by nitric oxide. Blood 2000;95:189\u201397.","journal-title":"Blood"},{"key":"5196_CR41","doi-asserted-by":"publisher","first-page":"e20170231","DOI":"10.1590\/1678-7757-2017-0231","volume":"26","author":"S Kanaya","year":"2018","unstructured":"Kanaya S, Xiao B, Sakisaka Y, Suto M, Maruyama K, Saito M, et al. Extracellular calcium increases fibroblast growth factor 2 gene expression via extracellular signal-regulated kinase 1\/2 and protein kinase A signaling in mouse dental papilla cells. J Appl Oral Sci. 2018;26:e20170231.","journal-title":"J Appl Oral Sci"},{"key":"5196_CR42","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1111\/jnc.13247","volume":"135","author":"N Kajitani","year":"2015","unstructured":"Kajitani N, Hisaoka-Nakashima K, Okada-Tsuchioka M, Hosoi M, Yokoe T, Morioka N, et al. Fibroblast growth factor 2 mRNA expression evoked by amitriptyline involves extracellular signal-regulated kinase-dependent early growth response 1 production in rat primary cultured astrocytes. J Neurochem. 2015;135:27\u201337.","journal-title":"J Neurochem"},{"key":"5196_CR43","doi-asserted-by":"publisher","first-page":"946","DOI":"10.1359\/jbmr.060309","volume":"21","author":"CF Li","year":"2006","unstructured":"Li CF, Hughes-Fulford M. Fibroblast growth factor-2 is an immediate-early gene induced by mechanical stress in osteogenic cells. J Bone Min Res. 2006;21:946\u201355.","journal-title":"J Bone Min Res"},{"key":"5196_CR44","doi-asserted-by":"publisher","first-page":"662","DOI":"10.1038\/s41419-020-02899-8","volume":"11","author":"CB Brashears","year":"2020","unstructured":"Brashears CB, Barlin M, Ehrhardt WR, Rathore R, Schultze M, Tzeng S-C, et al. Systems level profiling of arginine starvation reveals MYC and ERK adaptive metabolic reprogramming. Cell Death Dis. 2020;11:662.","journal-title":"Cell Death Dis"},{"key":"5196_CR45","doi-asserted-by":"publisher","first-page":"841","DOI":"10.1016\/S0008-6363(96)88621-4","volume":"29","author":"RF Morrison","year":"1995","unstructured":"Morrison RF, Seidel ER. Vascular endothelial cell proliferation: regulation of cellular polyamines. Cardiovascular Res. 1995;29:841\u20137.","journal-title":"Cardiovascular Res"},{"key":"5196_CR46","doi-asserted-by":"crossref","unstructured":"Nicosia RF, Belser P, Bonanno E, Diven J. Regulation of angiogenesis in vitro by collagen metabolism. Vitr Cell Developmental Biol: J Tissue Cult Assoc. 1991;27a:961\u20136.","DOI":"10.1007\/BF02631124"},{"key":"5196_CR47","doi-asserted-by":"publisher","first-page":"1481","DOI":"10.1111\/j.1471-4159.2007.04843.x","volume":"103","author":"V Pernet","year":"2007","unstructured":"Pernet V, Bourgeois P, Di Polo A. A role for polyamines in retinal ganglion cell excitotoxic death. J Neurochem. 2007;103:1481\u201390.","journal-title":"J Neurochem"}],"container-title":["Cell Death &amp; Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05196-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05196-8","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05196-8.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,8,29]],"date-time":"2022-08-29T11:03:12Z","timestamp":1661770992000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41419-022-05196-8"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,8,29]]},"references-count":47,"journal-issue":{"issue":"8","published-online":{"date-parts":[[2022,8]]}},"alternative-id":["5196"],"URL":"https:\/\/doi.org\/10.1038\/s41419-022-05196-8","relation":{},"ISSN":["2041-4889"],"issn-type":[{"value":"2041-4889","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,8,29]]},"assertion":[{"value":"16 February 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2022","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 August 2022","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 August 2022","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"AF, RBC, and RWC have a pending patent on the use of arginase 1 as a treatment for ischemic retinopathies. PN-MC is the chief executive officer of Bio-Cancer Treatment International Limited and holds stocks or shares in Bio-Cancer Treatment International Limited.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}},{"value":"All studies were approved by the Augusta University IACUC and IRB committees. Patients or guardians were consented before participation in the study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}}],"article-number":"745"}}